Richard A Lake

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 4

Top Topics

Escherichia Coli

Top Venues

Expert review of anticancer therapy

Science translational medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Rachael M Zemek, Wee Loong Chin, Vanessa S Fear, Ben Wylie, Thomas H Casey, Cath Forbes, Caitlin M Tilsed, Louis Boon, Belinda B Guo, Anthony Bosco, Alistair R R Forrest, Michael J Millward, Anna K Nowak, Richard A Lake, Timo Lassmann, Willem Joost Lesterhuis
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice. Nature communications 13 (1) (2022)
Alistair M Cook, Alison McDonnell, Michael J Millward, Jenette Creaney, Arman Hasani, Michelle McMullen, Tarek M Meniawy, Bruce W S Robinson, Richard A Lake, Anna K Nowak
A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert review of anticancer therapy 21 (5) (2021)
Rachael M Zemek, Emma De Jong, Wee Loong Chin, Iona S Schuster, Vanessa S Fear, Thomas H Casey, Cath Forbes, Sarah J Dart, Connull Leslie, Ayham Zaitouny, Michael Small, Louis Boon, Alistair R R Forrest, Daithi O Muiri, Mariapia A Degli-Esposti, Michael J Millward, Anna K Nowak, Timo Lassmann, Anthony Bosco, Richard A Lake, Willem Joost Lesterhuis
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Science translational medicine 11 (501) (2020)
Wayne J Aston, Danika E Hope, Alistair M Cook, Louis Boon, Ian M Dick, Anna K Nowak, Richard A Lake, Willem Joost Lesterhuis
Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. Oncoimmunology 8 (11) (2019)